A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants

The increased availability of tumor genetic testing and targeted cancer therapies contributes to the advancement of precision medicine in the field of oncology. Precision oncology knowledgebases provide a way of organizing clinically relevant genetic information in a way that is easily accessible for both oncologists and patients, facilitating the genetic-based clinical decision making. Many organizations and companies have built precision oncology knowledgebases, intended for multiple users. In general, these knowledgebases offer information on cancer-related genetic variants as well as their associated diagnostic, prognostic, and therapeutic implications, but they often differ in their information curations, designs, and user experiences. It is advisable that oncologists use multiple knowledgebases during their practice to have them complement each other. In the future, convergence toward common standards and formats is needed to ensure that the comprehensive knowledge across all sources can be unified to bring the oncology community closer to the achievement of the goal of precision oncology.

[1]  A. Kiss,et al.  Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Funda Meric-Bernstam,et al.  Personalized cancer therapy—leveraging a knowledge base for clinical decision-making , 2018, Cold Spring Harbor molecular case studies.

[3]  Dennis C. Friedrich,et al.  Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .

[4]  Rajendu Srivastava,et al.  A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs , 2016, Journal of oncology practice.

[5]  Corinna Ernst,et al.  Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics , 2018, BMC Medical Genomics.

[6]  M. Tuchman,et al.  Identification of ‘private’ mutations in patients with ornithine transcarbamylase deficiency , 1997, Journal of Inherited Metabolic Disease.

[7]  Charles Swanton,et al.  My Cancer Genome: a unified genomics and clinical trial portal , 2012 .

[8]  J Jack Lee,et al.  Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Adam Kiezun,et al.  Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine , 2013, Nature Medicine.

[10]  S. Ellard,et al.  Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. , 2010, Genetic testing and molecular biomarkers.

[11]  Li Ding,et al.  Database of evidence for precision oncology portal , 2018, Bioinform..

[12]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[13]  Harry Hochheiser,et al.  HemOnc: A new standard vocabulary for chemotherapy regimen representation in the OMOP common data model , 2019, Journal of Biomedical Informatics.

[14]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[15]  S. Patterson,et al.  Utility of the JAX Clinical Knowledgebase in capture and assessment of complex genomic cancer data , 2019, npj Precision Oncology.

[16]  Steven J. M. Jones,et al.  Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.

[17]  Md Abu Shufean,et al.  "Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource. , 2017, Cancer research.

[18]  Vincent Ferretti,et al.  Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial , 2013, International journal of cancer.

[19]  Li Ding,et al.  Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.

[20]  D. M. Hyman,et al.  Oncologist use and perception of large panel next-generation tumor sequencing , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  R. Jones,et al.  To be Therapeutic. , 1967 .

[22]  Funda Meric-Bernstam,et al.  Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology. , 2019, JCO clinical cancer informatics.

[23]  Jeremy L Warner,et al.  Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Marie-Cécile Le Deley,et al.  High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.

[25]  Gil Alterovitz,et al.  SMART Cancer Navigator: A Framework for Implementing ASCO Workshop Recommendations to Enable Precision Cancer Medicine. , 2018, JCO precision oncology.

[26]  Razelle Kurzrock,et al.  Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. , 2016, JAMA oncology.

[27]  Steven J. M. Jones,et al.  CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer , 2017, Nature Genetics.

[28]  Christine M. Micheel,et al.  The Path(way) Less Traveled: A Pathway-Oriented Approach to Providing Information about Precision Cancer Medicine on My Cancer Genome12 , 2016, Translational oncology.

[29]  Fei Ye,et al.  My Cancer Genome: Evaluating an Educational Model to Introduce Patients and Caregivers to Precision Medicine Information , 2016, CRI.

[30]  AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.

[31]  M. Krzyzanowska,et al.  Off-label use of cancer drugs: a benchmark is established. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Marcin Imielinski,et al.  The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations , 2016, J. Am. Medical Informatics Assoc..

[33]  E. Mardis,et al.  Prioritizing targets for precision cancer medicine. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Richard L Schilsky,et al.  Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Deborah Schrag,et al.  Precision Oncology: Who, How, What, When, and When Not? , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[36]  Karol Sikora,et al.  Personalized cancer therapy. , 2005, Personalized medicine.

[37]  R. Altman,et al.  PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. , 2005, Methods in molecular biology.

[38]  M. Levy,et al.  Integrating cancer genomic data into electronic health records , 2016, Genome Medicine.

[39]  Li Ding,et al.  Protein-structure-guided discovery of functional mutations across 19 cancer types , 2016, Nature Genetics.

[40]  Michael P. Schroeder,et al.  Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations , 2017, Genome Medicine.

[41]  Riccardo Bellazzi,et al.  A Semi-supervised Learning Approach for Pan-Cancer Somatic Genomic Variant Classification , 2019, AIME.

[42]  L. Hayden,et al.  Ten Commandments for Effective Clinical Decision Support: Making the Practice of Evidence-based Medicine a Reality , 2011 .

[43]  Niranjan Nagarajan,et al.  ConsensusDriver Improves upon Individual Algorithms for Predicting Driver Alterations in Different Cancer Types and Individual Patients. , 2018, Cancer research.

[44]  Shinichiro Suzuki,et al.  A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing , 2019, Scientific Reports.

[45]  Peng Gao,et al.  Comprehensive elaboration of database resources utilized in next-generation sequencing-based tumor somatic mutation detection. , 2019, Biochimica et biophysica acta. Reviews on cancer.

[46]  Jean Muller,et al.  Identification of 28 novel mutations in the Bardet–Biedl syndrome genes: the burden of private mutations in an extensively heterogeneous disease , 2010, Human Genetics.

[47]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[48]  Anuradha Lakshminarayana,et al.  The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies , 2016, Human Genomics.

[49]  David Bourque,et al.  Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non–Small Cell Lung Cancer Using a Clinicogenomic Database , 2019, JAMA.

[50]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[51]  Yuquan Wei,et al.  The Therapeutic Target Database: an Internet resource for the primary targets of approved, clinical trial and experimental drugs , 2011, Expert opinion on therapeutic targets.

[52]  Yves Sznajer,et al.  Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[53]  Subha Madhavan,et al.  A harmonized meta-knowledgebase of clinical interpretations of cancer genomic variants , 2018, bioRxiv.

[54]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[55]  Kenna R Mills Shaw,et al.  Clinical Use of Precision Oncology Decision Support. , 2017, JCO precision oncology.